October 9, 2024
7 Things to Know About DSCSA Enhanced Drug Distribution Security Requirements
The DSCSA: A Phased Approach to Implementation Published October 10th, 2024 Over a decade ago, the FDA established the Drug Supply Chain Security Act to help protect consumers from potentially counterfeit, stolen, contaminated, or otherwise harmful prescription drugs as they’re distributed throughout the United States. The legislation focuses on establishing procedures for achieving interoperable, electronic […]
October 2, 2024
Louisiana Board Report Sheds Light on DSCSA Compliance
A survey conducted by the Louisiana Board of Drug and Device Distributors (published on October 1st) found that a majority of trading partners have the necessary electronic systems to exchange data with other trading partners under the updated DSCSA compliance standards. The survey was sent to designated responsible persons (DRPs) at facilities that distribute drugs […]
September 26, 2024
Far From Compliant: Much Improvement Still Necessary for DSCSA Compliance
Many Manufacturers are Failing to Meet DSCSA Requirements Published September 26th, 2024 The November 27th, 2024 deadline for DSCSA Compliance is just two months away. While many pharmaceutical partners have made tremendous efforts to adhere to updated guidelines, many remain far from compliant. DSCSA Compliance is a team effort; if certain trading partners fail to […]
September 12, 2024
FDA: No More Delay for Updated DSCSA Guidelines
The FDA has reaffirmed its commitment to the November 27, 2024, deadline for pharmaceutical partners to adhere to upcoming DSCSA regulations. With time running out, pharmaceutical stakeholders must assess their readiness and address any outstanding challenges. Ensuring accurate and complete data exchange between trading partners is critical for DSCSA compliance. Yet many partners remain unprepared […]
September 4, 2024
The Importance of DSCSA Compliance
Many Unprepared for New Guidelines Published September 4th, 2024 With the November 27th, 2024 stabilization period deadline approaching quickly, pharmaceutical partners must be ready to adhere to new traceability and interoperability requirements. But a troubling number of partners haven’t made enough progress to reach these new standards, a statistic troubling to partners, the FDA, and […]
